Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIIB 
Biogen Inc (BIIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/10/2025: BIIB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
37 Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $171.72
1 Year Target Price $171.72
| 13 | Strong Buy |
| 4 | Buy |
| 20 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -2.2% | Avg. Invested days 40 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/10/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 21.49B USD | Price to earnings Ratio 14.03 | 1Y Target Price 171.72 |
Price to earnings Ratio 14.03 | 1Y Target Price 171.72 | ||
Volume (30-day avg) 37 | Beta 0.12 | 52 Weeks Range 110.04 - 194.13 | Updated Date 10/11/2025 |
52 Weeks Range 110.04 - 194.13 | Updated Date 10/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 15.31% | Operating Margin (TTM) 34.61% |
Management Effectiveness
Return on Assets (TTM) 5.62% | Return on Equity (TTM) 9.13% |
Valuation
Trailing PE 14.03 | Forward PE 9.69 | Enterprise Value 26597716339 | Price to Sales(TTM) 2.15 |
Enterprise Value 26597716339 | Price to Sales(TTM) 2.15 | ||
Enterprise Value to Revenue 2.66 | Enterprise Value to EBITDA 9.52 | Shares Outstanding 146614598 | Shares Floating 146224603 |
Shares Outstanding 146614598 | Shares Floating 146224603 | ||
Percent Insiders 0.15 | Percent Institutions 92.78 |
Upturn AI SWOT
Biogen Inc
Company Overview
History and Background
Biogen Inc. was founded in 1978 and is a pioneer in biotechnology. It has evolved from a research-focused company to a global leader in neuroscience, developing treatments for neurological and neurodegenerative diseases.
Core Business Areas
- Neurology: Focuses on developing therapies for multiple sclerosis (MS), spinal muscular atrophy (SMA), and other neurological conditions.
- Alzheimer's Disease: Dedicated to developing and commercializing treatments for Alzheimer's disease, including ADUHELM and LEQEMBI.
- Biosimilars: Develops and markets biosimilar versions of established biologic drugs.
Leadership and Structure
The leadership team is headed by the CEO. The organizational structure includes research and development, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- SPINRAZA: SPINRAZA is a treatment for spinal muscular atrophy (SMA). Competitors include Novartis' Zolgensma and Roche's Evrysdi. Revenue for 2023 was $1.72 billion. Estimated market share in the SMA treatment market is approximately 40-50%.
- TEC FIDERA: TECFIDERA (dimethyl fumarate) is a multiple sclerosis (MS) treatment. Competitors include other oral MS therapies from Novartis (Gilenya), Roche (Ocrevus) and Sanofi (Aubagio). While sales have declined due to generic competition, it generated revenue of $174 million in 2023.
- TYSABRI: TYSABRI (natalizumab) is a multiple sclerosis (MS) treatment. Competitors include other MS therapies from Novartis (Gilenya), Roche (Ocrevus) and Sanofi (Aubagio). generated revenue of $1.68 billion in 2023.
- LEQEMBI: LEQEMBI (lecanemab) is an Alzheimer's disease treatment. Primary competitor is Donanemab from Eli Lilly. Revenue for 2023 was minimal at $7 million, ramping up through 2024 and beyond as reimbursement and adoption grow.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and rapid technological advancements. The neuroscience segment is particularly focused on addressing unmet needs in areas like Alzheimer's disease, multiple sclerosis, and rare neurological disorders.
Positioning
Biogen is a major player in the neuroscience space, with a strong pipeline of potential new therapies and a well-established commercial infrastructure. Their competitive advantage stems from their research expertise, established brands, and strategic partnerships.
Total Addressable Market (TAM)
The global neurology market is estimated to be worth $35-40 billion, with continued growth projected. Biogen is positioned to capture a significant portion of this TAM through its existing products and pipeline.
Upturn SWOT Analysis
Strengths
- Strong presence in neuroscience
- Established brands
- Research and development capabilities
- Strong relationships with regulatory bodies
- Solid financial position
Weaknesses
- Reliance on a few key products
- Exposure to generic competition
- High R&D costs
- Regulatory risks associated with new drug approvals
- Past controversies surrounding drug pricing
Opportunities
- Expanding into new therapeutic areas
- Acquiring or licensing promising new technologies
- Developing biosimilars
- Partnering with other companies
- Expanding into emerging markets
Threats
- Increasing competition from other biotechnology companies
- Patent expirations
- Regulatory changes
- Economic downturns
- Unsuccessful clinical trials
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Novartis (NVS)
- Sanofi (SNY)
- Eli Lilly (LLY)
Competitive Landscape
Biogen faces strong competition in all its key therapeutic areas. It needs to innovate to retain its market leadership and protect its pipeline. Roche and Novartis are key competitors.
Major Acquisitions
Reata Pharmaceuticals
- Year: 2023
- Acquisition Price (USD millions): 7300
- Strategic Rationale: Expanded Biogenu2019s portfolio with Reatau2019s rare disease therapy, SKYCLARYS (omaveloxolone), approved for Friedreich's ataxia.
Growth Trajectory and Initiatives
Historical Growth: Biogen experienced significant growth in the past due to the success of its MS franchise. Growth has slowed in recent years due to patent expirations and increased competition.
Future Projections: Analysts project moderate growth in the coming years, driven by the launch of new products like LEQEMBI and potential pipeline advancements.
Recent Initiatives: Recent initiatives include focusing on LEQEMBI commercialization, streamlining operations, and investing in new research areas.
Summary
Biogen is a major player in neuroscience facing challenges from competition and patent expirations. The company is focusing on launching new products and streamlining operations to drive future growth. LEQEMBI is a key growth driver, but market adoption is crucial. Biogen has a solid financial position but needs to innovate to stay competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual circumstances and the advice of a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biogen Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1991-09-16 | President, CEO & Director Mr. Christopher A. Viehbacher | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 7605 | Website https://www.biogen.com |
Full time employees 7605 | Website https://www.biogen.com | ||
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.